Financing pushes Vancouver startup closer to clinical trials targeting diabetes, liver disease. Vancouver-based Aspect Biosystems has raised a $115-million USD ($165 million CAD) Series B round to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback